about
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesRepeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.TAS-102, a novel antitumor agent: a review of the mechanism of action.TAS-102 for the treatment of metastatic colorectal cancer.A novel antimetabolite: TAS-102 for metastatic colorectal cancer.TAS-102 an Emerging Oral Fluoropyrimidine.Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells.Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.Randomized trial of TAS-102 for refractory metastatic colorectal cancer.Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.[Initial Evaluation of the Efficacy and Safety of Tablets Containing Trifluridine and Tipiracil Hydrochloride--Safety Measures Devised by a Multidisciplinary Team Including a Pharmaceutical Outpatient Clinic]Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution
P921
Q26777679-950F5940-D1BC-44F0-8E3E-6126105795E0Q34439214-8CA95C4A-9136-4DE8-9900-F80471968020Q34473056-7B4ABD14-BEDD-43B7-B5C4-090D0BACC6E9Q36181265-0F0B2B10-8B2E-43FD-8C5D-12E9316EA5C6Q36621566-A333A6B8-2EF7-432B-A9FB-FDE0D78C8D7DQ38441129-FE5F5E2D-DEC2-4495-9A19-33D6E869B91BQ38597310-A3A618E7-D03C-4CD9-9D82-22CB49D4024DQ38618169-3F3C1A3D-8304-425A-A7D5-084788CBE5CFQ38671965-01E46884-5388-4230-B0A6-E7DABE92618CQ38684569-B11661B5-7C9D-41AC-8349-7DEDF681B29DQ38862939-E5239949-DD43-4187-8099-599CF5A0BDB8Q38883737-A01CBEEF-66FD-411F-9BE0-E7D4B648E73FQ38894690-8EE30B62-56CF-415E-826E-6DF0B826F0B9Q38902330-7C4558A4-DB0F-472D-BFD6-C66637AAF731Q41741632-E0C17780-98B5-46DD-8EA2-4C63214E17A4Q53386778-39220DB7-40E5-4EA5-BEDC-84A481F1609CQ85638475-4696F45A-7F61-401F-BFE6-CE1D20070637Q87001982-344837E0-04DD-43D2-A319-2C2976AA6303
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
tipiracil hydrochloride
@en
type
label
tipiracil hydrochloride
@en
altLabel
tipiracil monohydrochloride
@en
tipiracil.HCl
@en
prefLabel
tipiracil hydrochloride
@en
P592
P661
P662
P665
P683
P1579
P2067
P231
183204-72-0
P232
P233
C1CC(=N)N(C1)CC2=C(C(=O)NC(=O)N2)Cl.Cl
P234
1S/C9H11ClN4O2.ClH/c10-7-5(12- ...... h11H,1-4H2,(H2,12,13,15,16);1H
P235
KGHYQYACJRXCAT-UHFFFAOYSA-N
P2566
100.245.266
P274
C₉H₁₂Cl₂N₄O₂
P3345
P592
CHEMBL65375
P652
4H59KLQ0A4